Reversal of TGF-1stimulation of -smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's - Derived fibroblasts

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Satish, Latha ^a   Gallo, Phillip H ^a   Baratz, Mark E ^b   Johnson, Sandra ^a   Kathju, Sandeep ^a  

^a ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; FIBRONECTIN; FORSKOLIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, HUMAN; ACTIN; ADENYLATE CYCLASE; ALPHA 2(I) COLLAGEN; COL3A1 PROTEIN, HUMAN; CTGF PROTEIN, HUMAN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; RECOMBINANT PROTEIN; SCLEROPROTEIN;

ARTICLE; CARPAL TUNNEL SYNDROME; CELL TYPE; DISEASE COURSE; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; EXTRACTION; FIBROBLAST; HUMAN; HUMAN CELL; MYOFIBROBLAST; PALMAR FASCIA; PHENOTYPE; PROTEIN DOMAIN; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECT; ENZYME ACTIVATION; FASCIA; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTINS; ADENYLATE CYCLASE; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CARPAL TUNNEL SYNDROME; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DUPUYTREN CONTRACTURE; ENZYME ACTIVATION; ENZYME ACTIVATORS; EXTRACELLULAR MATRIX PROTEINS; FASCIA; FIBRONECTINS; FORSKOLIN; HUMANS; MYOFIBROBLASTS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80955176384     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-113     Document Type: Article

References (46)

1. Assessment of clinical severity in Dupuytren's disease. A Bayat EJ Cunliffe DA McGrouther, Br J Hosp Med 2007 68 604 609 (Pubitemid 350195878)
2. Cellular structure and biology of Dupuytren's disease. JJ Tomasek MB Vaughan CJ Haaksma, Hand Clin 1999 15 21 34 10050239 (Pubitemid 29066101)
3. Permanent retraction of the fingers, produced by an affection of the palmar fascia. Clinical lectures on surgery. G Dupuytren, Lancet 1884 2 222
4. TGF-beta:possible roles in Dupuytren's contracture. P Kloen CL Jennings MC Gebhardt DS Springfield HJ Mankin, J Hand Surg 1995 20A 101 108
5. Dupuytren's contracture: a new concept of the pathogenesis correlated with surgical management. JV Luck, J Bone Joint Surg [Am] 1959 41-A 635 664
6. Pathogenesis of Dupuytren's contracture: a correlative clinic-pathological study. HF Chiu RM McFarlane, J Hand Surg 1978 3 1 10 (Pubitemid 8283397)
7. Cellular biology. W Schürch O Skalli G Gabbiani, Dupuytren's disease: biology and treatment London: Churchill Livingstone, McFarlane RM, McGrouther DA, Flint MH, 1990 31 47 21617556
8. Mechanisms of myofibroblast activity and phenotypic modulation. G Serini G Gabbiani, Exp Cell Res 1999 250 273 283 10.1006/excr.1999.4543 10413583 (Pubitemid 29367440)
9. Regulation of expression of alpha-smooth muscle actin in cells of Dupuytren's contracture. HB Hindman R Marty-Roix JB Tang JB Jupiter BP Simmons M Spector, J Bone Joint Surg Br 2003 85 448 455 10.1302/0301-620X.85B3.13219 12729127 (Pubitemid 36511602)
10. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. DW Powell RC Mifflin JD Valentich SE Crowe JI Saada AB West, Am J Physiol 1999 277 1 C9 10409103
11. The role of TGF-beta in Dupuytren's disease. MA Badalamente SP Sampson LC Hurst A Dowd K Miyasaka, J Hand Surg 1996 21A 210 215
12. Presence of growth factors in palmar and plantar fibromatoses. RL Zamaro R Heights BA Kraemer HP Ehrlich JP Groner, J Hand Surg 1994 19A 435 441 (Pubitemid 24164552)
13. TGF-beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. A Berndt H Kosmehl U Mandel U Gabler X Leo D Celeda L Zardi D Katenkamp, Histochem J 1995 27 1014 1020 8789403 (Pubitemid 26040135)
14. Treatment of Dupuytren's contracture-long-term results after fasciotomy and fascial excision. JJ Rodrigo JJ Niebauer RL Brown JR Doyle, J Bone Joint Surg 1976 58A 380 387
15. Dupuytren's contracture: an audit of the outcomes of surgery. JJ Dias J Braybrooke, J Hand Surg 2006 31B 514 521 (Pubitemid 44321360)
16. Efficacy and safety of injectable missed collagenase subtypes in the treatment of Dupuytren's contracture. MA Badalamente LC Hurst, J Hand Surg 2007 32A 767 774 (Pubitemid 46991162)
17. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study. RH Gelberman D Amiel RM Rudolph RM Vance, J Bone Joint Surg 1980 62A 425 432 (Pubitemid 10094194)
18. Structure and function of cyclic nucleotide-dependent protein kinases. SH Francis JD Corbin, Ann rev Physiol 1994 56 237 272 10.1146/annurev.ph.56. 030194.001321 (Pubitemid 24111861)
19. Transcriptional regulation by cyclic AMP. M Montminy, Annu Rev Biochem 1997 66 807 822 10.1146/annurev.biochem.66.1.807 9242925 (Pubitemid 27274675)
20. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. X Liu RS Ostrom PA Insel, Am J Physiol 2004 286 1089 C1099
21. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. JS Swaney DM Roth ER Olson JE Naugle GJ Meszaros PA Insel, Proc Natl Acad Sci USA 2005 102 437 442 10.1073/pnas.0408704102 15625103 (Pubitemid 40116785)
22. Wound healing-assoociated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. JC Howard VM Varallo DC Ross KJ Faber JH Roth S Seney BS Gan, J Surg Res 2004 117 232 238 10.1016/j.jss.2004.01.013 15047128 (Pubitemid 38393648)
23. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. L Satish WA Laframboise DB O'Gorman S Johnson B Janto BS Gan ME Baratz FZ Hu JC Post GD Ehrlich S Kathju, BMC Med Genomics 2008 1 10 10.1186/1755-8794-1-10 18433489
24. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. M Böhm M Raghunath C Sunderkötter M Schiller S Ständer T Brzoska T Cauvet HB Schiöth T Schwartz TA Luger, J Biol Chem 2004 279 6959 6966 14645373 (Pubitemid 38248839)
25. Increased cAMP levels modulate TGF-/Smad-induced expression of extracellular matrix components and other key fibroblast functions. M Schiller S Dennler U Anderegg A Kokot JC Simon TA Luger A Mauviel M Böhm, J Biol Chem 2010 285 409 421 10.1074/jbc.M109.038620 19858184
26. Age-dependent differential expression of fibronectin variants in skin and airway mucosal wounds. HS Li-Korotky PA Hebda CY Lo JE Dohar, Arch Otolaryngol Head Neck Surg 2007 133 919 924 10.1001/archotol.133.9.919 17875859 (Pubitemid 47437280)
27. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Pannu S Nakerakanti E Smith P ten Dijke M Trojanowska, J Biol Chem 2007 282 10405 14013 10.1074/jbc.M611742200 17317656
28. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. A Leask A Holmes CM Black DJ Abraham, J Biol Chem 2003 278 13008 13015 10.1074/jbc.M210366200 12571253 (Pubitemid 36800068)
29. Identification of novel TGF-beta/SMAD gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transctivation approach. F Verrecchia ML Chu A Mauviel, J Biol Chem 2001 276 17058 17062 10.1074/jbc.M100754200 11279127
30. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. A Holmes DJ Abraham S Sa X Shiwen CM Black A Leask, J Biol Chem 2001 276 10594 10601 10.1074/jbc.M010149200 11152469 (Pubitemid 38089227)
31. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. RJ Alioto RN Rosier RI Burton JE Puzas, J Hand Surg Am 1994 19 442 452 10.1016/0363-5023(94)90059-0 8056971 (Pubitemid 24164553)
32. Revised tubiana's staging system for assessment of disease severity in dupuytren's disease-Preliminary clinical findings. S Hindocha JK Stanley JS Watson A Bayat, Hand 2008 3 80 86 10.1007/s11552-007-9071-1 18780081
33. Nonooperative treatment of Dupuytren's disease. LC Hurst MA Badalamente, Hand Clinic 1999 15 97 107
34. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. LC Hurst MA Badalamente VR Hentz RN Hotchkiss FT Kaplan RA Meals TM Smith J Rodzvilla CORD I Study Group, N Engl J Med 2009 361 968 979 10.1056/NEJMoa0810866 19726771
35. Dupuytren's disease. A model for the mechanism of fibrosis and its modulation by steroids. RM Meek S McLellan JF Crossan, J Bone Joint Surg Br 1999 81 732 738 10.1302/0301-620X.81B4.9163 10463754
36. The effect of steroids on Dupuytren's disease: role of programmed cell death. RM Meek S McLellan J Reilly JF Crossan, J Hand Surg Br 2002 27 270 273 10.1054/jhsb.2001.0742 12074617 (Pubitemid 34863354)
37. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. LD Ketchum TK Donahue, J Hand Surg Am 2000 25 1157 1162 11119679
38. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. B Jemec C Linge AO Grobbelaar PJ Smith R Sanders DA McGrouther, Chir Main 2000 19 15 22 10.1016/S1297-3203(00)73455-X 10777424 (Pubitemid 30216914)
39. A prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of dupuytren's disease. NW Bulstrode M Bisson B Jemec AL Pratt DA McGrouther AO Grobbelaar, J Hand Surg Br 2004 29 18 21 10.1016/j.jhsb.2003.08.002 14734063 (Pubitemid 38180639)
40. Abnormal growth factor and cytokine expression in Dupuytren's contracture. KS Baird F Crossan SH Ralston, J Clin Pathol 1993 46 425 428 10.1136/jcp.46.5.425 8320323 (Pubitemid 23167416)
41. Connective-tissue growth factor (CTGF) modulates cell signaling by BMP and TGF-beta. JG Abreu NI Ketpura B Reversade EM De Robertis, Nature Cell Biol 2002 4 599 604 12134160
42. Connective tissue growth factor (CTGF/CCN2) is a downstream mediator for TGF-beta1-induced extracellular matrix production in osteoblasts. JA Arnott E Nuglozeh MC Rico I Arango-Hisijara PR Odgren FF Safadi SN Popoff, J Cell Physiol 2007 210 843 852 10.1002/jcp.20917 17133352 (Pubitemid 46185053)
43. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. S Chujo F Shirasaki S Kawara Y Inagaki T Kinbara M Inaoki M Takigawa K Takehara, J Cell Physiol 2005 203 447 456 10.1002/jcp.20251 15605379 (Pubitemid 40471779)
44. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. GR Grotendorst, Cytokine Growth Factor Rev 1997 8 171 179 10.1016/S1359-6101(97)00010-5 9462483 (Pubitemid 28077925)
45. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. M Sisco ZB Kryger KD O'Shaughnessy PS Kim GS Schultz XZ Ding NK Roy NM Dean TA Mustoe, Wound Repair Regen 2008 16 661 673 10.1111/j.1524-475X.2008.00416.x 19128261
46. Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. M Schiller F Verrecchia A Mauviel, Oncogene 2003 22 8881 8890 10.1038/sj.onc.1206871 14654784 (Pubitemid 38021504)